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Available online 19 April 2006Diazoxide has been identified as a mitochondrial, ATP-dependent K+ channel opener, and a
potentially neuroprotective compound under ischemic conditions. We set out to
characterize the consequences of various treatment strategies with diazoxide in a rat
model of chronic cerebral hypoperfusion. Cerebral hypoperfusion was induced by
permanent, bilateral occlusion of the common carotid arteries (2VO, n = 36), sham-
operated rats serving as controls (SHAM, n = 29). Diazoxide or its vehicle was administered i.
p. daily (5 × 0.5mg/kg/0.25ml) or as a bolus injection (5mg/kg/0.25ml) before surgery or daily
after surgery (5 × 0.5mg/kg/0.25ml). Spatial learning performancewas assessed 1week after
2VO in the Morris maze. Hippocampal pyramidal cell loss was assessed on cresyl violet-
stained sections, while glial reactivity was labeled immunocytochemically. Daily or bolus
pretreatment with diazoxide significantly improved 2VO-related learning impairment,
whereas posttreatmentwas ineffective. The number of CA1 pyramidal neuronswas reduced
by 2VO, which was prevented by repeated or bolus pretreatment with diazoxide. Astrocyte
proliferation and microglial activation were enhanced by posttreatment with diazoxide in
the hippocampus CA1 area of 2VO animals as compared with SHAM. These data
demonstrate that the neuroprotective effect exerted by diazoxide depends on the time of
administration with respect to the onset of ischemia; pretreatment but not posttreatment
with the compound has proved to be neuroprotective in chronic cerebral hypoperfusion.
Thus, pretreatment with diazoxide offers therapeutical prospects for the treatment of
cerebral ischemia.
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169B R A I N R E S E A R C H 1 0 8 7 ( 2 0 0 6 ) 1 6 8 – 1 7 41. IntroductionDiazoxide, a mitochondrial, ATP-dependent K+ (mKATP)
channel opener, has originally been used in clinical practice
in hypertensive emergencies (Goodman Gilman et al., 1990).
By now, an accumulating body of experimental data has
demonstrated that diazoxide can be used for pharmacolog-
ical preconditioning, attenuating ischemic heart damage
(O'Rourke, 2004). In view of its preventive action in cardiac
ischemia, diazoxide has become the focus of recent
investigation as a potential anti-ischemic agent in the
brain. The growing interest in the pharmacological action
of diazoxide on the central nervous system was encouraged
by the finding that the brain contains a considerably higher
concentration of mKATP channels (the target of diazoxide)
than other peripheral organs (Bajgar et al., 2001).
Compelling evidence of the neuroprotective effect of
diazoxide has emerged from experiments on brain slices or
neuronal cell cultures, where diazoxide applied before
oxygen and glucose deprivation enhanced the cell viability
and preserved the electrophysiological properties of the
hippocampal neurons (Zawar and Neumcke, 2000; Kis et al.,
2003). Although neuroprotection on cell cultures and the
intracellular pathways initiated by diazoxide have been
documented in detail (Busija et al., 2004), little is known
about the neuroprotective potential of diazoxide at the
level of the brain. To date, only a few studies have
administered diazoxide to experimental animals with the
aim of examining the effect of the drug on the ischemic
brain. In this way, diazoxide has been shown to limit the
infarct size after middle cerebral artery occlusion or
unilateral carotid artery occlusion combined with hypoxia
in rodents (Liu et al., 2002; Rajapakse et al., 2002; Shimizu
et al., 2002). Despite these preliminary data, no clear
evidence has been gathered as to whether diazoxide can
actually prevent the cognitive dysfunction after an ische-
mic insult, and whether the cognitive status correlates with
histologic neural markers. Furthermore, most studies have
applied diazoxide as pretreatment because of its known
effects of acute and delayed pharmacologic preconditioning
(Busija et al., 2004). Although diazoxide pretreatment has
thus appeared to be a neuroprotective strategy of promise
in cerebral ischemia, it is of interest from a therapeutic
point of view to establish whether postischemic adminis-
tration of the drug can also exert beneficial effects on the
central nervous system.
In the present study, we followed previously devised
methods (Farkas et al., 2004; 2005a,b) to identify the
potentially neuroprotective effects of diazoxide in a rat
model of chronic cerebral hypoperfusion. Since our previ-
ous work had focused on the effect of diazoxide at a late
phase of chronic cerebral ischemia, our present objective
was to investigate the action of diazoxide at an early
phase of cerebral hypoperfusion. Further, as diazoxide had
been administered only as posttreatment in our previous
experiments (while others had used it only as pretreat-
ment), in the present study, we also set out to compare
the neural effects of pretreatment and posttreatment with
diazoxide.2. Results
The spatial learning curves obtained with the Morris maze
test demonstrated that 2 weeks of experimental cerebral
hypoperfusion induced a marked decrease in learning
performance in the non-treated 2VO group as compared
with the non-treated SHAM group (Fig. 1A). Both repeated
and bolus pretreatment with diazoxide improved the
spatial memory. The 2VO animals that received either
repeated or bolus diazoxide pretreatment exhibited the
same performance as concerns the average swimming
distance as compared with their respective SHAM controls,
specifically on days 2, 3, and 5 (Figs. 1B and C). Conversely,
the 2VO animals that received diazoxide posttreatment did
not succeed in learning the Morris maze paradigm. On days
2 and 5, the 2VO rats posttreated with diazoxide achieved sig-
nificantly worse results as compared with the corresponding
SHAM posttreated group (Fig. 1D).
Corresponding with the results of the learning test,
cerebral hypoperfusion induced a moderate but constant
loss of hippocampal CA1 pyramidal neurons (Fig. 2).
Although massive necrotic cell death was not detected, the
CA1 str. pyramidale in the 2VO animals displayed a loose
cellular arrangement as compared with the compact struc-
ture of the pyramidal layer in the SHAM animals (Figs. 2A
and B). Cell counting revealed that 2VO decreased pyramidal
cell number with 6%. Both the repeated and the bolus
pretreatment with diazoxide preserved the compact struc-
ture of the CA1 str. pyramidale (Fig. 2C) and prevented
pyramidal cell loss (Fig. 2D).
GFAP-immunoreactive astrocytes were present in all the
hippocampal regions and in all the experimental groups.
Neither 2VO nor pretreatment with diazoxide exerted a
detectable influence on the GFAP immunoreactivity in the
investigated hippocampal areas. However, posttreatment
with diazoxide doubled the GFAP signal in the CA1 str.
radiatum and str. oriens of the 2VO rats (Fig. 3).
Activated microglia labeled with OX-42 were scarce not
only in the SHAM animals but also in the 2VO non-treated rats
in all regions of the hippocampus. In contrast, dense staining
was detected in the CA1 str. oriens and str. radiatum of the
2VO animals posttreated with diazoxide (Figs. 4A–C). Quanti-
tative analysis demonstrated that the application of diazoxide
after 2VO increased the OX-42 signal approximately 2.5-fold in
the CA1 str. oriens and 7-fold in the CA1 str. radiatum as
compared with the SHAM groups (Figs. 4D and E).3. Discussion
The present study has revealed that pretreatment with dia-
zoxide at the dose of 5 × 0.5 mg/kg or 1 × 5 mg/kg, given i.p. is
neuroprotective as regards chronic cerebral hypoperfusion in
rats. The neuroprotective action of the pretreatment with
diazoxide was reflected in an improvement in spatial learning
performance and the inhibition of pyramidal cell loss in the
hippocampus CA1 region.
Our line of investigation is novel in the sense that the action
of diazoxide on learning andmemory has not previously been
Fig. 1 – The results of the Morris water maze spatial orientation test. Data are presented as means ± SEM; *P < 0.05, **P < 0.01.
Abbreviations: 2VO: permanent, bilateral common carotid artery occlusion (two-vessel occlusion); C: control for treatment;
DIAZ: diazoxide; post: posttreatment; pre: pretreatment; SHAM: sham-operated control.
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present results demonstrate that diazoxide prevents the
cerebral hypoperfusion-related learning dysfunction when
administered as pretreatment. However, posttreatment with
diazoxide exerted no clear effect on the learning perfor-
mance, similarly as we earlier observed at a later time point
in cerebral hypoperfusion (Farkas et al., 2005a). The finding
that pretreatment with diazoxide has a beneficial effect on
learning, and the integrity of the hippocampal pyramidal
cells is in accord with the pharmacological action of
diazoxide revealed in studies on cultured neurons. The
pretreatment of neurons with diazoxide before oxygen-
glucose deprivation increased their viability as compared
with that of non-treated cultures (Nagy et al., 2004).
Diazoxide is known to depolarize the mitochondria and to
simultaneously elevate the production of reactive oxygen
species, which is assumed to play a significant role in the
preconditioning effect of diazoxide (Busija et al., 2004). The
transient, moderate elevation of the concentration of
reactive oxygen species by diazoxide is suggested to
condition the cells to be able to tolerate a later, robust
ischemic event better. Such preconditioning may account for
the preserved learning performance and enhanced hippo-
campal neuronal viability of 2VO rats following pretreatment
with diazoxide.
The immunocytochemical signals for both astrocytes and
microglia were markedly enhanced by posttreatment with
diazoxide in the 2VO animals, while 2VO or diazoxide alone
had no effect on the glial cells. This suggests that, given the
sequence of 2VO and treatment, diazoxide was able tostimulate the glial cells, provided that the glia were already
made sensitive by ischemia.
Although the lack of evidence means that it is difficult to
establish a causal link between treatment with diazoxide and
a glial reaction, the intriguing observation was made that a
subpopulation of reactive astrocytes expressed a Ca2+-acti-
vated, ATP-sensitive nonselective cation channel (NCCa-ATP)
under hypoxic conditions. Interestingly, these channels are
controlled by a sulfonylurea regulatory subunit, SUR1, which
is the target of diazoxide. It has been shown that the
treatment of such astrocytes with diazoxide results in
activation of the NCCa-ATP channels, which are suggested to
control the swelling and migration of astrocytes in hypoxic
nervous tissue (Chen et al., 2003). Even though a strict corre-
lation cannot be drawn with our data, a similar mechanism
may play a role in the diazoxide-induced astrocytic prolifer-
ation shown here.
The background of diazoxide-related microglial activation
is even more obscure. Although the activity of the microglia is
dependent on the opening state of the surface ion channels
(Eder, 1998), regulatory SUR subunits (the potential sites of the
action of diazoxide) have not been associated with these
channels. Further, microglial activation is accompanied by an
increased number and elongated shape of mitochondria
(Banati et al., 2004), but a potential contribution of mitochon-
drial K+ currents to these processes has not been identified,
yet. Finally, the existing data on the effect of diazoxide on
microglial activation in cerebral hypoperfusion are inconsis-
tent: posttreatment with diazoxide prevents microglial acti-
vation at a late time point in cerebral hypoperfusion (Farkas et
Fig. 2 – Cresyl violet staining and cell counting in the
hippocampus CA1 str. pyramidale. (A–C) Representative
photomicrographs of the hippocampal CA1 area from
pretreated animals. (D) Quantitative data on pyramidal cell
viability in the hippocampus CA1 str. pyramidale; area unit
is 0.024 mm2 (3 × 10 grid holes at 40× magnification). Data
are presented as means ± SEM; *P < 0.05. The P value
indicated in the graph was obtained with a Student's t test.
Abbreviations: 2VO: permanent, bilateral common carotid
artery occlusion (two-vessel occlusion); C: control for
treatment; DIAZ: diazoxide; pre: pretreatment; SHAM:
sham-operated control.
171B R A I N R E S E A R C H 1 0 8 7 ( 2 0 0 6 ) 1 6 8 – 1 7 4al., 2004, 2005a,b), while the same treatment enhances
microglial activation at an early time point, as shown here.
This may suggest that the effect of diazoxide on ischemia-
relatedmicroglial activation is defined by the time of sampling
with respect to the treatment and the onset of cerebral
hypoperfusion.
The concentration of diazoxide was chosen to be low
enough to exclude potentially harmful side effects such as
hypotension, reduced cerebral blood flow or hyperglycemia,
which are known to potentiate ischemic injury. Recent results
have demonstrated that the plasma glucose level and mean
arterial pressure in rats are not significantly affected by even
6mg/kg diazoxide i.p. (Lenzsér et al., 2005). A selective effect of
a low dose of diazoxide on the brain is probably due to the
distribution and molecular composition of the mKATP chan-
nels. The brain contains a 6–7 times higher concentration of
mKATP channels than the liver or the heart (Bajgar et al., 2001).
Our present observation that a low concentration of diazoxide
attenuates ischemic hypoperfusion-induced brain damage,
yet does not alter the vascular andmetabolic parameters, may
be of therapeutic potential in cerebral ischemia.In conclusion, we have found that a low dose of diazoxide
that is ineffective on the mean arterial pressure or blood
glucose concentration (Lenzsér et al., 2005) is potent on the
central nervous system. Further, diazoxide prevents an
ischemia-induced learning impairment when the drug is
administered as pretreatment, but not as posttreatment.
Finally, diazoxide potentiates glial reactivity when given as
posttreatment, but not as pretreatment. The present findings
on the glial reaction call for further research on the mechan-
isms of action of diazoxide on glia cells. Our results may
additionally provoke investigations on the neuroprotective
properties of diazoxide with therapeutical prospects in
ischemia.4. Experimental procedures
Sixty-five male Wistar rats (302 ± 18 g) were used for the
study. All animal experiments were approved by the ethical
committee of the University of Szeged. Chronic, experimen-
tal cerebral hypoperfusion was induced in half of the
animals by permanent bilateral occlusion of the common
carotid arteries (2VO), the other half serving as sham-
operated controls (SHAM) (Farkas et al., 2004). Prior to
surgery, the animals were anesthetized with 400 mg/kg
chloralhydrate i.p., followed by 0.05 ml 0.1% atropine i.m.
The common carotid arteries were exposed via a ventral
cervical incision, carefully separated from their sheaths and
vagal nerves, and permanently ligated with surgical sutures.
Lidocaine (1%) was applied as local anesthetic. The same
procedure was performed on the SHAM group but without
the actual ligation.
The animals were treated with diazoxide or its vehicle
(0.25 ml 0.1 N NaOH), i.p. In the first group, diazoxide (0.5 mg/
kg/0.25 ml) or its vehicle was injected on 5 consecutive days
immediately before 2VO surgery. In the second group,
diazoxide (5 mg/kg/0.25 ml) was administered once (bolus)
the day before 2VO surgery. In the third group, diazoxide
(0.5 mg/kg/0.25 ml) or its vehicle was injected on 5 consec-
utive days after 2VO surgery, the first injection given within
1 h following surgery. The final compositions of the
experimental groups and the survival rates are presented in
Table 1.
One week following 2VO surgery, the animals were
trained in the Morris water maze (Farkas et al., 2004),
which consisted of a circular pool (diameter: 160 cm,
depth: 35 cm) filled with water (22 °C), made opaque with
milk so that the rats were unable to see an underwater
platform 2 cm below the water surface. Invariant visual cues
were placed on the wall of the testing room, and an auditory
source with a fixed location was switched on throughout the
testing. All the rats performed two trials per day, with a
constant inter-trial interval of 4 h, for 5 consecutive days.
The starting positions were selected at random from four
standard entry points. The rats were given 2 min to find the
platform and sit on it for 15 s. Rats that failed to find the
location within the given time were gently guided to the plat-
form and allowed to stay on it for 15 s. Swimming paths were
recorded with a computerized video imaging analysis system
(EthoVision, Noldus Information Technology BV,Wageningen,
Fig. 3 – GFAP immunocytochemistry for astrocyte proliferation. (A–C) Representative photomicrographs of the hippocampal
CA1 area from posttreated animals. (D) Quantitative data on GFAP immunocytochemistry in the hippocampal CA1 str. oriens of
the posttreated animals. (E) Quantitative data on GFAP immunocytochemistry in the hippocampal CA1 str. radiatum of the
posttreated animals. Data are presented asmeans ± SEM; *P < 0.05, **P < 0.01. Abbreviations: 2VO: permanent, bilateral common
carotid artery occlusion (two-vessel occlusion); C: control for treatment; DIAZ: diazoxide; post: posttreatment; SHAM:
sham-operated control.
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swimming distance traveled before the rats reached the
platform were analyzed.Fig. 4 – OX-42 immunocytochemistry relating to microglia activa
hippocampal CA1 area from posttreated animals. (D) Quantitativ
CA1 str. oriens of the posttreated animals. (E) Quantitative data o
radiatum of the posttreated animals. Data are presented as mea
permanent, bilateral common carotid artery occlusion (two-vess
posttreatment; SHAM: sham-operated control.Seven days after the beginning of the Morris water maze
training, and14days after theperformanceof 2VO, theanimals
were reanesthetized with an overdose of chloralhydrate (i.p.)tion. (A–C) Representative photomicrographs of the
e data on OX-42 immunocytochemistry in the hippocampal
n OX-42 immunocytochemistry in the hippocampal CA1 str.
ns ± SEM; *P < 0.05, **P < 0.01. Abbreviations: 2VO:
el occlusion); C: control for treatment; DIAZ: diazoxide; post:













Pretreatment SHAM-C 6 5 83
2VO-C 9 8 89
SHAM-DIAZ 8 6 75




Posttreatment SHAM-C 7 6 86
2VO-C 7 6 86
SHAM-DIAZ 8 7 88
2VO-DIAZ 8 6 75
Abbreviations: 2VO: permanent, bilateral common carotid artery
occlusion (two-vessel occlusion), C: control for treatment, DIAZ:
diazoxide, SHAM: sham-operated control.
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400 ml 3.5% paraformaldehyde and 0.5% picric acid in 0.1 M
phosphate buffer (PB, pH 7.4). The brains were removed and
postfixed in the same solution for up to 1 h and then stored in
0.1 M PB containing 0.1% sodium azide.
Free-floating coronal sections at the level of the dorsal
hippocampuswere cut at 20-μmthickness on a cryostat. Three
sections per animal that contained the dorsal hippocampus
(Bregma −3.60, Paxinos and Watson, 1986) were mounted on
gelatine-coated microscopic slides and stained with cresyl
violet.
A second set of sections was stained immunocytoche-
mically for glial fibrillary acidic protein (GFAP) to visualize
the astrocytic proliferation. Briefly, sections were treated
with 3% H2O2 and 0.5 Triton X-100 in 0.01 M PBS and
preincubated in 20% normal pig serum (NPS). The samples
were then incubated overnight at RT in a primary antibody
solution containing mouse anti-GFAP antibody (Sigma), 1:40
000, 20% NPS, and 0.03% merthiolate in 0.01 M PBS. The
secondary antibody solution consisted of goat anti-mouse
biotinylated IgG (Jackson), 1:400, 10% NPS, 5% normal rabbit
serum and 0.03% merthiolate in 0.01 M PBS. Finally, the
sections were incubated in STA-PER (Jackson), 1% NPS, and
0.03% merthiolate in 0.1 M Tris buffer, and the color reaction
was conventionally developed with diaminobenzidine (DAB)
and H2O2.
To detect and analyze the microglial activation over the
hippocampal areas, OX-42 antibody was used on a third set
of sections. The procedure started with rinsing and
pretreating the sections with 0.5% Triton X-100 and 3%
H2O2 in 0.01 M PBS, followed by preincubation in 20%
normal NPS and 0.5% Triton X-100 in 0.01 M PBS for 1 h.
The sections were incubated overnight in a primary
antibody solution containing biotinylated mouse anti-
CD11b antibody (OX-42, Serotec), 1:500, 20% NPS, and 0.03%
merthiolate in 0.01 M PBS at RT. Next, the sections were
rinsed and incubated in a solution of STA-PER (Jackson), 1%
NPS, and 0.03% merthiolate in 0.1 M Tris buffer for 1 h at RT.
Finally, the color reaction was developed with Ni-DAB and
H2O2. All the sections were mounted on gelatin-coated
microscopic slides, air-dried, dehydrated, and coverslipped
with DPX.The number of pyramidal neurons in the hippocampus
CA1 region was counted with the help of an ocular grid at 40×
magnification on a surface of 0.024mm2 (3 × 10 grid holes) that
covered the entire diameter of the CA1 str. pyramidale. Cell
counting was performed bilaterally on three consecutive brain
sections. The six values were averaged, and the average was
used for further statistical analysis.
The percentage surface areas of GFAP-positive astrocytes
and OX-42-immunoreactive microglia in the dorsal hippo-
campus were quantified by using a computerized image
analysis system (Olympus BX50, DP50, software: ImagePro
Plus, Media Cybernetics, U.S.A.). Briefly, three consecutive
coronal sections at Br. −3.60 mm (Paxinos and Watson, 1986)
were selected for the analysis. Hippocampal regions of interest
were delineated manually at 10× magnification, after back-
ground subtraction and gray scale threshold determination.
The area covered by immunoreactive material was computed
as a percentage of the total area delineated. Measurements
were carried out on both sides of the hippocampus. Six values
per animal per area were averaged, and the average was used
for further statistical analysis. The following areas were
analyzed separately: the CA1 str. radiatum, the CA1 str. oriens,
the CA3 str. radiatum, the CA3 str. oriens, the inner and outer
molecular layers of the dentate gyrus, and the hilus.
TheMorris maze test results were analyzed statistically via
the repeated measures of the general linear model of the
software SPSS. Individual daily comparisons were performed
by analysis of variance (ANOVA) followed by the LSD post hoc
test. The immunocytochemical results were analyzed statis-
tically with two-way ANOVA for surgery and treatment,
followed by the LSD post hoc test.Acknowledgments
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